Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application.
OBJECTIVE
The aim of this study was to compare the efficacy of a 1-hour(h) versus 1-day application of topical moxifloxacin in eliminating conjunctival bacterial flora.


METHODS
In this prospective, nonrandomized, controlled trial, the surgical eyes of 60 patients scheduled for intraocular surgery received topical moxifloxacin four times a day, starting 1 day prior to surgery and three additional applications at 5-minute intervals 1 h before surgery. The nonsurgical eye of each patient only received three applications of the same antibiotic at 5-minute intervals 1 h before surgery. Conjunctival cultures were obtained at baseline and after antibiotic application.


RESULTS
Prior to antibiotic application, 80% of surgical eyes and 70% of nonsurgical eyes had positive cultures. Following the 1-day application, significantly fewer eyes (40%) had positive cultures (P < 0.0001), with a further reduction to 32% with three additional doses 1 h prior to surgery. In the nonsurgical eye, the decrease in the percentage of positive cultures, from 55% to 53% following the three applications 1 h prior to surgery, was not significant (P > 0.9999). The 1-day application was associated with significantly fewer positive cultures, compared to the 1-h group (P = 0.0267).


CONCLUSIONS
The one-day application of moxifloxacin resulted in significantly fewer positive conjunctival cultures, compared with a 1-h application.
Ta
Christopher N
CN
Department of Ophthalmology, School of Medicine, Stanford University, Stanford, CA 94304, USA. cta@stanford.edu
Chan
Ian
I
Dhatt
Harpreet Singh
HS
Paterno
Josemaria
J
Fisher
Emily
E
Singh
Kuldev
K
Montague
Artis
A
Egbert
Peter R
PR
Cockerham
Glenn
G
Kaspar
Herminia Mino De
HM
D000287:Administration, Topical; D000368:Aged; D001372:Aza Compounds / Q000008:administration & dosage*; D003234:Conjunctivitis, Bacterial / Q000188:drug therapy* / Q000382:microbiology*; D004334:Drug Administration Schedule; D015818:Eye Infections, Bacterial / Q000188:drug therapy / Q000382:microbiology; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D000077266:Moxifloxacin; D011446:Prospective Studies; D011804:Quinolines / Q000008:administration & dosage*; D013997:Time Factors
D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin